Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Targeting Tau in Alzheimer's Disease and Related Disorders

Targeting Tau in Alzheimer's Disease and Related Disorders

Monday, March 13, 2017

The New York Academy of Sciences

The microtubule associated protein tau (MAPT) is a key mediator of neurodegeneration in Alzheimer’s disease and related disorders. This symposium will address the potential of tau-related targets for immunotherapy, across the spectrum of tauopathies. We will review the pre-clinical and clinical development of several tau immunotherapy programs that exemplify this emerging therapeutic strategy for Alzheimer’s disease and other devastating neurodegenerative disorders.

Reception to follow.

Registration Pricing

Member (Student / Postdoc / Resident / Fellow)$25
Nonmember (Academia)$105
Nonmember (Corporate)$160
Nonmember (Non-profit)$105
Nonmember (Student / Postdoc / Resident / Fellow)$70

This event will also be broadcast as a webinar; registration is required.

Please note: Transmission of presentations via the webinar is subject to individual consent by the speakers. Therefore, we cannot guarantee that every speaker's presentation will be broadcast in full via the webinar. To access all speakers' presentations in full, we invite you to attend the live event in New York City where possible.

Webinar Pricing

Member (Student / Postdoc / Fellow)$15
Nonmember (Academia)$65
Nonmember (Corporate)$85
Nonmember (Non-profit)$65
Nonmember (Student / Postdoc / Fellow)$45


* Presentation times are subject to change.

Monday, March 13, 2017

8:30 AM

Breakfast and Registration

9:00 AM

Introduction and Welcome Remarks
Sonya Dougal, PhD, The New York Academy of Sciences
Robert Martone, St Jude Children's Research Hospital

9:15 AM

Keynote Address
What Tau Immunization Is Likely to Bring?
Khalid Iqbal, PhD, New York State Institute for Basic Research

Session 1

10:00 AM

Tau's Anatomical Footprints and Biochemical Signatures
Bernardino Ghetti, MD, Indiana University School of Medicine

10:35 AM

Networking Coffee Break

11:05 AM

Mechanisms of Tau Immunotherapies
Einar M. Sigurdsson, PhD, NYU School of Medicine

Data Blitz Session

11:40 AM

Receptor Mediated Prion-like Propagation of PH-Tau
Viktoriya Morozova, College of Staten Island, The City University of New York
* Presenter slides will not be included as part of the webinar broadcast

11:50 AM

Transcranial Two-Photon Imaging of Tau Antibodies and Tau Aggregates in the Brains of Live Transgenic Tauopathy Mice
Qian Wu, PhD, NYU School of Medicine

12:00 PM

Networking Lunch and Poster Session

Session 2

1:30 PM

Active Vaccination Strategies to Prevent and Reverse Alzheimer's Disease
Michael G. Agadjanyan, PhD, DSc, The Institute for Molecular Medicine

2:05 PM

Fluid Biomarkers for Tau Pathology in Alzheimer's Disease
Henrik Zetterberg, MD, PhD, University of Gothenburg

2:40 PM

Networking Coffee Break

3:10 PM

Mechanisms of Pathological Tau Release in Tau Transgenic Mice and AD Synaptosomes
Emanuele Sher, MD PhD, Neuroscience Discovery, Lilly
* Presenter slides will not be included as part of the webinar broadcast

3:45 PM

Panel Discussion
Moderator: Khalid Iqbal, PhD, New York State Institute for Basic Research
Michael G. Agadjanyan, PhD, DSc, The Institute for Molecular Medicine
Einar M. Sigurdsson, PhD, NYU School of Medicine
Henrik Zetterberg, MD, PhD, University of Gothenburg

4:30 PM

Closing Remarks and F1000 Research Poster Prize Award
Khalid Iqbal, PhD, New York State Institute for Basic Research

4:40 PM

Networking Reception

5:40 PM



Khalid Iqbal, PhD

New York State Institute for Basic Research in Developmental Disabilities

Khalid Iqbal is Professor and Chairman, Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. His pioneering studies on neuronal protein pathology and discoveries of tau protein and its abnormal hyperphosphorylation in Alzheimer disease have won him many prestigious honors and awards, including the Potamkin Prize for Alzheimer Disease research from the American Academy of Neurology, the Zenith Award from the Alzheimer's Association, U.S.A. and Honorary Doctor of Science degree from the City University of New York College of Staten Island. In 2007, Alzheimer's Association, USA, established a Khalid Iqbal Life Time Achievement Award for Alzheimer's Disease Research, which is given out annually at the International Conference on Alzheimer's Disease (ICAD) to a senior established Alzheimer disease researcher. Dr. Iqbal has authored over 400 scientific papers in prestigious American and international scientific journals and edited seven books on research advances in Alzheimer disease and related neurodegenerative disorders. He currently serves on the editorial boards of several journals and scientific advisory committees of biotechnology companies.

Robert Martone

St Jude Children's Research Hospital

Robert Martone conducts biomarker research and development with a focus on neuro-oncology in the Department of Pathology at St. Jude Children's Research Hospital. He was previously Neuroscience Therapeutic Area Lead for the Covance Biomarker Center of Excellence. He has extensive experience in the pharmaceutical industry leading neuroscience drug discovery and technology teams through all phases of discovery from target identification through clinical trials with expertise in both small molecule and protein therapeutics. He also has several years of academic research experience in molecular neurobiology, with a focus on the molecular genetics of familial neuropathies, and CNS tumor biomarker development.

Sonya Dougal, PhD

The New York Academy of Sciences

Caitlin McOmish, PhD

The New York Academy of Sciences


Michael G. Agadjanyan, PhD, DSc

The Institute for Molecular Medicine

Dr. Michael G. Agadjanyan is Vice President, Professor and Head of the Department of Molecular Immunology at the Institute for Molecular Medicine, in Huntington Beach, California and an Adjunct Professor at the MiND Institute at the University of California, Irvine. At his previous faculty position at the Department of Pathology and Laboratory Medicine at the University of Pennsylvania he was an integral member of the development team for a novel DNA vaccination technique. For the last 17 years Dr. Agadjanyan has used his vast experience in immunology and vaccine development for generating and testing different DNA and recombinant protein vaccines targeting various B cell epitopes of pathological Aβ, tau, a-syn. Currently Dr. Agadjanyan's team plans to complete nonclinical safety/toxicology, biodistribution/persistence, MRI studies supported by U01 NIA program in 2 years and obtain approval of IND for AV-1959D Phase 1 clinical trial from the FDA. Other DNA and recombinant protein vaccines targeting Aβp3-11 as well as various tau and a-syn B cell epitopes are at different stages of the development at IMM and UCI MiND.

Bernardino Ghetti, MD

Indiana University School of Medicine

Dr. Bernardino Ghetti, MD, obtained his Doctorate in Medicine and completed the Specialization in Mental and Nervous Diseases at the University of Pisa, Italy. At the Albert Einstein College of Medicine, Bronx, New York, he received training as a research fellow in experimental Neuropathology and then as a resident in Pathology and Neuropathology. Throughout his career, Dr. Ghetti has investigated neurodegenerative dementias, using human tissue and animal models. Dr. Ghetti's approach begins with the neuropathologic analysis: the identification of the brain's neurodegenerative changes determines the direction of the molecular investigations at the protein and DNA levels and has led to the identification of the etiological basis of several forms of dementia. In 1989, he discovered the first hereditary dementia, characterized by the coexistence of prion protein amyloid and neurofibrillary tangles. Subsequently, Dr. Ghetti's team identified genetic mutations in the APP, PSEN1, PRNP, and other genes causing neurodegeneration. In 1993, Dr. Ghetti began studying a hereditary form of frontotemporal dementia, characterized by tau deposits in neurons and glia. In 1998, by identifying the genetic defect, causing that disorder, Dr. Ghetti's international team was among the first to discover mutations in the MAPT gene. Dr. Ghetti, Distinguished Professor at Indiana University, is the founder of the Indiana Alzheimer Disease Center and served as its first Director (1991–2013). Dr. Ghetti served as President of the American Association of Neuropathologists, the International Society of Neuropathology. He is the Founder and served as the first President of the International Society for Frontotemporal Dementias.

Khalid Iqbal, PhD

New York State Institute for Basic Research in Developmental Disabilities

Viktoriya Morozova, BS

College of Staten Island, The City University of New York

Viktoriya Morozova is a graduate student in the Master's Program in the Center for Developmental Neuroscience at the College of Staten Island, City University of New York. In 2008, she received an AS from Kingsborough Community College and in 2015 she completed her BS in Biology from the College of Staten Island. In 2013, Viktoriya joined the lab of Dr. Alejandra Alonso and began studying the mechanism of neuronal loss in Alzheimer's disease as a function of tau expression. She has been awarded first place in Graduate Conference on Research and Scholarship. Her current focus in the lab is to analyze the prion-like propagation of tau in culture and in a mouse model of tauopathy.

Einar M. Sigurdsson, PhD

New York University School of Medicine

Einar M. Sigurdsson, PhD is a Professor of Neuroscience and Physiology, and Psychiatry at New York University School of Medicine. A native of Iceland, he received a master's degree in Pharmacy (Cand. Pharm.) from the University of Iceland, and a PhD in Pharmacology from Loyola University Chicago Medical Center. He subsequently obtained postdoctoral training at New York University School of Medicine. His honors include a Zenith Fellows Award and the Margaret M. Cahn Research Award from the Alzheimer's Association, the Irma T. Hirschl Career Scientist Award, and several NIH grant awards as principal investigator. He presently serves as a standing member of an NIH study section and Specialty Chief Editor of Frontiers in Neurodegeneration. His current research focuses on pathogenesis, therapy and diagnosis for age-related protein conformational disorders, in particular Alzheimer's disease, and most recently includes exploratory studies in Parkinson's disease and related synucleinopathies. Dr. Sigurdsson and his collaborators pioneered the use of modified amyloid-β derivatives as potential immunotherapy for Alzheimer's disease. Furthermore, they showed for the first time that active and passive immunization as well as chelators delayed the onset of prion disease in mice. On the diagnostic front, Dr. Sigurdsson and colleagues published the initial report on detection of amyloid plaques in living mouse brains by magnetic resonance imaging. Lately, he has pioneered the approach to harness the immune system to target pathological tau protein in Alzheimer's disease and other tauopathies.

Emanuele Sher, MD, PhD

Lilly UK

Emanuele (Many) received his MD degree from the University of Milan, Italy, a PhD from Oxford Brookes University, UK, and post-doctoral training in Germany and the USA. He got a permanent position as a Researcher at the Italian National Research Council and later he was appointed as adjunct Professor of Physiology at the University of Turin. He joined Eli Lilly in Surrey, UK in 1997 as a head of the electrophysiology group. Many’s group developed over the years a variety of biochemical, electrophysiological and imaging techniques to study ion channels, GPCR and enzyme targets, with a focus on neuronal excitability, synaptic transmission and synaptic plasticity. Utilizing these techniques Many’s laboratory supported several Neuroscience drug discovery efforts at Lilly in both the Neurodegeneration and the Pain therapeutic areas. Many directly led several internal discovery projects, as well as external collaborations, both academic and industrial, nationally and internationally.

Qian Wu, PhD

New York University School of Medicine

Dr. Qian Wu is a postdoctoral researcher in Dr. Einar Sigurdsson's laboratory at New York University School of Medicine. Respectively in 2008 and 2009, Dr. Wu received her dual BS degrees in Pharmaceutic Science and Psychology from the School of Pharmaceutical Sciences and the Department of Psychology, Peking University, China. Then she obtained her MS degree in Pharmacology from Peking University in 2010. After that, she earned her PhD degree in Neuroscience from Rutgers University–Robert Wood Johnson Medical School. Her current research is focused on studying the mechanisms and functional effects of tau immunotherapies in mouse models.

Henrik Zetterberg, MD, PhD

University of Gothenburg, Sweden

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at the Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, and his main research focus and clinical interest is fluid biomarkers for CNS disorders.


Active Vaccination Strategies to Prevent and Reverse Alzheimer's Disease
Michael G. Agadjanyan, PhD, DSc, Institute for Molecular Medicine, Huntington Beach, CA; and the Institute for Memory Impairments and Neurological Disorders, UC Irvine

Following the exciting first report on a successful vaccine preventing AD progression in an animal model of AD in 1999, various vaccines targeting beta amyloid (Aβ), tau, and α-Synuclein (α-syn) have proceeded to human clinical trials with mixed results. Unfortunately, unlike the comprehensive data published on AN-1792 vaccine trials by various groups, only the limited data on immunizations of AD patients with epitope vaccines composed of the small B cell epitopes form Aβ, tau, and α-syn peptides attached to a carrier molecule are available in current scientific literature. This lack of comprehensive immunological data prevents the accurate assessment of efficacy of vaccines in AD patients. More specifically, current data suggest that to be effective the vaccine should induce therapeutically relevant concentrations of antibodies targeting appropriate pathological molecules (e.g., Aβ, tau, a-syn) in elderly people with immunesenescence. In this presentation, from the standpoint of immunologists and vaccine researchers, we will discuss the various pitfalls and misconceptions encountered on the path to the successful AD epitope vaccine: (i) better standardization of immunological efficacy measures of anti-Aβ, anti-tau, and anti-α-syn vaccines; (ii) better methods to improve vaccine immunogenicity such as more immunogenic platform/carrier; and (iii) the new adjuvants required to achieve this breakthrough. We suggest that given the roles of Aβ, tau, and α-syn molecules on AD pathology and progression of disease, anti-Aβ active vaccination may be more effective in the very early stage of a disease including prodromal AD, while anti-tau and anti-α-syn immunotherapies or their combinations to be most effective in the later stages of AD.
Coauthor: Anahit Ghochikyan, Institute for Molecular Medicine, Huntington Beach, California.

Tau's Anatomical Footprints and Biochemical Signatures
Bernardino Ghetti, MD, Indiana University School of Medicine

Intracellular filamentous Tau inclusions accumulate in several human sporadic and inherited neurodegenerative diseases. They may occur also in some postinfectious and post-traumatic syndromes. Involved are neurons and glia, in different combinations, according to disease entity. Six Tau isoforms are expressed in adult human brain. They are produced by alternative mRNA splicing of transcripts from MAPT, the Tau gene, and differ by the presence or absence of inserts of 29 or 58 amino acids in the amino-terminal half, and the inclusion or not, of the 31 amino-acid repeat encoded by exon 10 in the carboxy-terminal half. Inclusion of exon 10 results in the production of three Tau isoforms with four repeats each (4R), and its exclusion in three isoforms with three repeats each (3R). Tau pathology occurs either as a primary event or concomitantly with a cerebral amyloidosis. Filamentous Tau differs according to disease entity and may be composed by any of the following: 3R, 4R, or 3R&4R isoforms. When Tau pathology represents the primary event, the Tau anatomical footprint varies along with the 3R, 4R, or 3R&4R signatures. Both gray and white matter may display Tau deposits in the presence of 3R or 4R signatures. The white matter pathology is severe in association with the 4R Tau signature, but not in association with the 3R&4R signature. When Tau pathology occurs concomitantly with amyloidosis, as in Alzheimer disease and in some prion diseases, the Tau signature is 3R&4R, and the anatomical footprint of Tau may be determined by the amyloid's footprint.

Mechanisms of Tau Immunotherapies
Einar M. Sigurdsson, PhD, New York University School of Medicine

The field of tau immunotherapies has advanced from proof-of-concept studies (Sigurdsson EM, R01AG020197, 2001; Asuni, AA et al, J Neurosci 2007) to clinical trials by several groups. Clearing pathological tau may be more effective in the later stages of Alzheimer's disease than removing amyloid-β, because tau pathology correlates better with cognitive impairment than amyloid-β burden. Even though clinical trials are ongoing, the mechanisms involved are not well defined. Numerous tau epitopes have been targeted with vaccines/antibodies for clearance in various models. Interestingly, most but not all approaches are effective, even when targeting the same epitope region, and higher affinity does not necessarily translate to better efficacy. Importantly as well, some antibodies appear to work primarily extracellularly whereas others can also bind to and clear/neutralize tau intracellularly. Because most of pathological tau is found within neurons, such broadly acting antibodies are likely to be more efficacious than those that can only bind to tau in the interstitial fluid. Furthermore, it is well known that antibody humanization alters its properties, and the preclinical findings to date in the tau field suggest that such engineering may substantially affect its biodistribution and efficacy. Therefore, those antibodies need to be examined carefully prior to clinical trials. These therapeutic studies have also sparked development of antibody derivatives as imaging probes, which should be more specific than the β-sheet dye compounds that are in clinical trials, and may then allow tailoring the immunotherapy to the most prevalent pathological tau epitopes in each individual.

What Tau Immunization Is Likely to Bring
Khalid Iqbal, PhD, New York State Institute for Basic Research in Developmental Disabilities

Alzheimer's disease (AD) is a slow progressive multifactorial disorder in which neurodegeneration is associated with neurofibrillary tangles of abnormally hyperphosphorylated tau (ptau), and Abeta core-neuritic (senile) plaques. Hippocampus is most affected with tau pathology and neurodegeneration in AD. In human brain tau is expressed in six alternatively spliced isoforms. In AD all six isoforms of tau are abnormally hyperphosphorylated. Tau pathology in the absence of Abeta pathology is a hallmark of a family of neurodegenerative disorders, called tauopathies. Without exception tau pathology is made up of hyperphosphorylated protein. Thus, it is reasonable to expect that inhibition of tau pathology by immunotherapy can inhibit neurodegeneration and rescue cognitive impairment. Given the involvement of six isoforms there are multiple possible patterns of tau hyperphosphorylation. Unlike normal tau which binds to microtubule protein subunit tubulin and promotes its assembly and stabilizes the microtubule network, the ptau instead binds to normal tau and templates it in a prion-like fashion into tau oligomers and filaments. We took advantage of this finding and carried out immunization with tau antibodies targeting the amino-terminal domains of tau. We found that with this strategy we can rescue not only tau but also Abeta pathology and cognitive impairment in 3×Tg-AD mouse model of AD. Furthermore, we found that the immunotherapy can also prevent the spread of AD-ptau induced pathology in tau transgenic mice. Thus, immunization targeting the amino-terminal domain of tau has the potential to lead to an effective treatment for AD and related tauopathies.

Receptor Mediated Prion-like Propagation of PH-Tau
Viktoriya Morozova, BS, Center for Developmental Neuroscience, College of Staten Island, CUNY

Alzheimer disease starts in hippocampus and progresses in well-defined pattern, a mechanism of cellular transmission is suspected. It has been shown that hyperphosphorylation of tau at Ser199, Thr212, Thr231 and Ser262 (PH-Tau) is sufficient to induce a tau pathological conformation, a structural change similar to that found in Alzheimer's. To investigate if tau can be an agent responsible for disease transmission we used two different strategies: 1) addition of the purified recombinant tau and/or PH-Tau to a cell culture medium; and 2) co-culture cells transfected with RFP-tau or GFP-PH-Tau. When recombinant protein was added to the media, we observed that both tau and PH-Tau are readily incorporated into HEK cells. The same results were found in primary neuronal culture. Additionally, we found that pretreatment of cells and primary neurons with the broad muscarinic receptor antagonist Atropine led to a great reduction of extracellular tau uptake. During co-culture, we observed that GFP-PH-Tau but no RFP-tau was released from the cells and was uptaken by neighboring cells, disrupting their cytoskeleton. These experiments suggest that PH-tau can be secreted from cells and transferred to normal cell transmitting the disease in a "prion-like" fashion through muscarinic receptors which may mediate the endocytotic mechanism.
Coauthor: Alejandra del C. Alonso, Center for Developmental Neuroscience, College of Staten Island, CUNY.

Transcranial Two-Photon Imaging of Tau Antibodies and Tau Aggregates in the Brains of Live Transgenic Tauopathy Mice
Qian Wu, PhD, New York University School of Medicine

Tau immunotherapies are a promising approach for Alzheimer's disease and related tauopathies. Our group published the first reports showing the effectiveness of active and passive tau immunizations in mouse models. These findings have been confirmed and extended by several groups and clinical trials have already been initiated. However, the mechanisms of antibody-mediated clearance of tau aggregates are relatively unclear, although work by us and others has clarified to some extent in culture models various pathways that may be involved. Two monoclonal antibodies (mAbs) that we have generated against the P-Ser396, 404 tau region, 4E6 and 6B2, have markedly different properties. 4E6 is more effective in various culture, ex vivo and in vivo models in preventing/reducing tau pathology and associated cognitive impairments, whereas 6B2 or rather its smaller derivatives may be better suited as a diagnostic imaging marker. Here, using in vivo two-photon imaging, we investigated the dynamics of brain uptake and clearance of fluorescently tagged 4E6 and 6B2 in live transgenic tauopathy mice. Our preliminary two-photon findings show neuronal uptake and colocalization of tau mAbs and a tau aggregate imaging dye 1-fluoro-2,5-bis (3-carboxy-4-hydroxystyryl) benzene (FSB) within the brain after intravenous injection. Based on clearance of the FSB signal, 4E6 is more efficacious in clearing tau pathology than 6B2, which fits our published findings (Congdon et al., Mol Neurodegener, 2016).This type of approach provides valuable insight into the dynamics of uptake and clearance of mAbs as well as their pathological targets in live animals, and may clarify their mechanism of action.
Coauthors: Yan Lin, Jiaping Gu, and Einar M. Sigurdsson, New York University School of Medicine.

Fluid Biomarkers for Tau Pathology in Alzheimer's Disease
Henrik Zetterberg, MD, PhD, University of Gothenburg, Mölndal, Sweden; Sahlgrenska University Hospital, Mölndal, Sweden; and UCL Institute of Neurology, Queen Square, London

Tau is a microtubule-binding protein that is important for the stability of neuronal axons. It is normally expressed within neurons and is also secreted into the brain interstitial fluid that communicates freely with cerebrospinal fluid (CSF) and, in a more restricted manner, blood via the glymphatic clearance system of the brain. In Alzheimer's disease (AD), neuroaxonal degeneration results in increased release of tau from neurons. Further, tau may be truncated and phosphorylated, which leads to aggregation of tau in neurofibrillary tangles of the proximal axoplasm. Neuroaxonal degeneration and tangle formation are reflected by increased concentrations of total tau (T-tau, measured using assays that detect most forms of tau) and phospho-tau (P-tau, measured using assays with antibodies specific to phosphorylated forms of tau). In AD CSF, both T-tau and P-tau concentrations are increased. In stroke and other CNS disorders with neuroaxonal injury but without tangles, T-tau is selectively increased, whilst P-tau concentration often stays normal. In tauopathies (diseases with both neurodegeneration and neurofibrillary tangles) other than AD, CSF T-tau and P-tau concentrations are typically unaltered, which is a puzzling result that warrants further investigation. In the current presentation, I discuss the association of T-tau and P-tau concentrations in body fluids with neuropathological changes, imaging findings and clinical features in AD and other CNS diseases. I will also cover the latest developments in the detection of novel tau species in biofluids and how they may reflect disease onset and progression.

Mechanisms of Pathological Tau Release in Tau Transgenic Mice and AD Synaptosomes
Emanuele Sher, MD, PhD, Eli Lilly and Company, Lilly Research Centre, United Kingdom

Tau is a microtubule binding protein expressed mainly in axons and nerve terminals. Mutations in tau are known to cause different "tauopathies" while tau aggregates and tangles are a hallmark of Alzheimer's disease (AD). Tau accumulation in synapses can cause early functional deficits, while Tau "spreading" along connected neuronal populations seems to correlate with cognitive decline in AD patients.
Our aim is to understand if and how synapses are affected by pathological tau and how tau spreading occurs at these synaptic sites. To study the physiological status of tau containing synapses, AD brain synaptosomes were injected in Xenopus oocytes and their functional properties analysed by two-electrode voltage clamp. Synaptic transmission was studied in hippocampal slices from tg4510 mice. Biochemical studies were performed on synaptosomes purified from transgenic mice (P301S and tg4510) and human control and AD subjects. Significant functional deficits were found in AD synaptosomes micro transplanted in oocytes, Synaptic deficits were also found in hippocampal slices from the tg4510 mice. Hyper-phosphorylated and aggregated tau (sarcosyl-insoluble, AT8+ and MC1+) was found in synaptosomes from both transgenic mice and human AD brains. Super-resolution single synapse imaging analysis confirmed that pathological tau is enriched in the presynaptic compartment. Pathological tau is released in a calcium dependent manner and its release is prevented by different botulinum toxins, confirming its vesicular nature.
A better understanding or the mechanism(s) of tau accumulation at, and release from, synapses could lead to novel therapeutic interventions aiming at reducing tau propagation and disease progression in AD.

Travel & Lodging

Our Location

The New York Academy of Sciences

7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157

Directions to the Academy

Hotels Near 7 World Trade Center

Recommended partner hotel

Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133

The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.

Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.

Other nearby hotels

Conrad New York


Millenium Hilton


Marriott Financial Center


Club Quarters, Wall Street


Eurostars Wall Street Hotel


Gild Hall, Financial District


Wall Street Inn


Ritz-Carlton New York, Battery Park